Hansen H H, Dombernowsky P, Hansen M, Hirsch F
Ann Intern Med. 1978 Aug;89(2):177-81. doi: 10.7326/0003-4819-89-2-177.
A controlled clinical trial compared three-drug and four-drug combination chemotherapy in 109 patients with advanced small-cell anaplastic carcinoma of the lung. The combination of vincristine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), cyclophosphamide, and methotrexate was significantly superior to the combination of the last three drugs alone with regard to median survival (230 versus 176 days) (P less than 0.01) and to duration of response (186 versus 112 days) (P less than 0.01). Objective response occurred in 78% and 75%, respectively. No significant difference in these values was observed in the comparison of the three subtypes of small-cell anaplastic carcinoma using the World Health Organization classification.
一项对照临床试验比较了109例晚期肺间变性小细胞癌患者接受三药联合化疗和四药联合化疗的效果。长春新碱、1-(2-氯乙基)-3-环己基-1-亚硝基脲（CCNU）、环磷酰胺和甲氨蝶呤联合使用在中位生存期（230天对176天）（P<0.01）和缓解持续时间（186天对112天）（P<0.01）方面显著优于仅使用后三种药物联合。客观缓解率分别为78%和75%。在使用世界卫生组织分类法对间变性小细胞癌的三种亚型进行比较时，未观察到这些数值有显著差异。
